China's Hua Medicine plans $400 million Hong Kong IPO, led by Goldman, say sources: Reuters
Chinese drug developer Hua Medicine is planning to raise at least $400 million in an initial public offering in Hong Kong in the latest in a series of biotech floats in the city, sources told Reuters.
9 March 2018•3 mins read
